Allergan Says State Laws Doom Restasis Payors' Class Push
Allergan told a New York federal judge that a group of Restasis buyers can't certify their class claims accusing the pharmaceutical giant of boosting profits by delaying a cheaper generic version...To view the full article, register now.
Already a subscriber? Click here to view full article